GL1X · GenesisL1 explorer

MolNFT v1 · #48979 · protein

4-substituted trinems as broad spectrum-lactamase inhibitors: structure-based design, synthesis and biological activity

2Q9M · Beta-lactamase: “4-substituted trinems as broad spectrum-lactamase inhibitors: structure-based design, synthesis and…”. X-ray diffraction, 1 ligand (LK7), 3 pockets (best druggability 0.66). MolNFT v1 #48979 on GenesisL1: 3D…

PDB
2Q9M
Type
protein
Length
359 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Beta-lactamase
EC
3.5.2.6
UniProt
P05364
Ligands
LK7
Pockets
3 · best druggability 0.66

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 22% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABeta-lactamase (EC 3.5.2.6)protein35940% helix, 22% strandP05364

Ligands and binding sites

  • LK7 · (1r,4s,7as)-1-(1-formylprop-1-en-1-yl)-4-methoxy-2,4,5,6,7,7A-hexahydro-1H-isoindole-3-carboxylic acid · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13650.660.8044LK7
2820.320.7418empty
3530.270.7416empty

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 2Q9M · 4-Substituted Trinems as Broad Spectrum-Lactamase Inhibitors: Structure-based Design… · the same entry in another collection · chain A against A, TM-score 1.00
  • P05364 · AlphaFold monomer V2.0 prediction for beta-lactamase (P05364) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.